Modular Bioprocess Platforms for Gene-Edited Therapies.

To make enough gene-edited therapies for more patients and to treat more diseases, bioprocessing is moving to more flexible methods. “The biggest problem in getting these products to patients remains manufacturing,” says Jason C. Foster, CEO of Ori Biotech, which recently announced a collaboration with MaxCyte to improve and accelerate the production of CRISPR-edited T cells.